Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
701.85
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
208
Open
701.85
Bid (Size)
679.00 (1)
Ask (Size)
741.00 (1)
Prev. Close
701.85
Today's Range
701.85 - 701.85
52wk Range
693.00 - 1,211.20
Shares Outstanding
91,779,465
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
December 22, 2024
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.
Via
Benzinga
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
December 19, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
-22.45%
-22.45%
1 Month
-4.90%
-4.90%
3 Month
-35.73%
-35.73%
6 Month
-34.03%
-34.03%
1 Year
-17.38%
-17.38%
More News
Read More
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
December 17, 2024
Via
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
November 26, 2024
Via
Benzinga
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
November 19, 2024
Via
Benzinga
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study
December 17, 2024
Via
Benzinga
Exposures
Product Safety
Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts
December 17, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
December 17, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
November 18, 2024
Via
Benzinga
Check Out What Whales Are Doing With REGN
November 15, 2024
Via
Benzinga
28 Analysts Have This To Say About Regeneron Pharmaceuticals
November 14, 2024
Via
Benzinga
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
December 16, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
December 16, 2024
Via
Investor's Business Daily
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
December 09, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
December 07, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
December 04, 2024
Via
Benzinga
It’s Been A Tough Month For Healthcare Stocks
December 02, 2024
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
November 27, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
November 26, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Not-So-Big Pharma
November 16, 2024
Via
Talk Markets
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
November 15, 2024
Via
Benzinga
Exposures
Product Safety
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
November 15, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Top Growth Stocks to Buy on the Dip
November 14, 2024
Via
The Motley Fool
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
November 13, 2024
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.